Nanoflares Detect Live Tumor Cells in Human Blood
By LabMedica International staff writers Posted on 07 Dec 2014 |
Image: NanoFlares-specially designed stem cells that have been developed to detect blood-borne cancers. When the cells come in contact with cancerous cells, they emit light (Photo courtesy of the International Institute for Nanotechnology at Northwestern University).
Metastasis portends a poor prognosis for cancer patients and primary tumor cells disseminate through the bloodstream before the appearance of detectable metastatic lesions.
The analysis of cancer cells in blood, the so-called circulating tumor cells (CTCs), may provide unprecedented opportunities for metastatic risk assessment and investigations using NanoFlares, when coupled with flow cytometry, can be used to fluorescently detect genetic markers of CTCs in the context of whole blood.
Scientists at Northwestern University (Evanston, IL, USA) working with colleagues from various institutions, used NanoFlare technology designed to recognize a specific genetic code snippet associated with a cancer. The core nanoparticle, only 13 nanometers in diameter, enters cells, and the NanoFlare seeks its target. The genetic targets were messenger RNA (mRNA) that code for certain proteins known to be biomarkers for aggressive breast cancer cells.
The team first used the blood of healthy individuals, spiking some of the blood with living breast cancer cells to see if the NanoFlares could detect them and they used unspiked blood as a control. They tested four different NanoFlares, each with a different genetic target relevant to breast cancer metastasis. Samples were analyzed by flow cytometry using the LSRFortessa Analyzer (BD Biosciences; San Jose, CA, USA). The technology successfully detected the cancer cells with less than 1% incidence of false-negative results.
Chad A. Mirkin, PhD, the director of the Institute of Nanotechnology and senior author of the study said, “This technology has the potential to profoundly change the way breast cancer in particular and cancers in general are both studied and treated. Cancers are very genetically diverse, and it's important to know what cancer subtype a patient has. Now you can think about collecting a patient's cells and studying how those cells respond to different therapies. The way a patient responds to treatment depends on the genetic makeup of the cancer.” The study was published on November 17, 2014, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
Northwestern University
BD Biosciences
The analysis of cancer cells in blood, the so-called circulating tumor cells (CTCs), may provide unprecedented opportunities for metastatic risk assessment and investigations using NanoFlares, when coupled with flow cytometry, can be used to fluorescently detect genetic markers of CTCs in the context of whole blood.
Scientists at Northwestern University (Evanston, IL, USA) working with colleagues from various institutions, used NanoFlare technology designed to recognize a specific genetic code snippet associated with a cancer. The core nanoparticle, only 13 nanometers in diameter, enters cells, and the NanoFlare seeks its target. The genetic targets were messenger RNA (mRNA) that code for certain proteins known to be biomarkers for aggressive breast cancer cells.
The team first used the blood of healthy individuals, spiking some of the blood with living breast cancer cells to see if the NanoFlares could detect them and they used unspiked blood as a control. They tested four different NanoFlares, each with a different genetic target relevant to breast cancer metastasis. Samples were analyzed by flow cytometry using the LSRFortessa Analyzer (BD Biosciences; San Jose, CA, USA). The technology successfully detected the cancer cells with less than 1% incidence of false-negative results.
Chad A. Mirkin, PhD, the director of the Institute of Nanotechnology and senior author of the study said, “This technology has the potential to profoundly change the way breast cancer in particular and cancers in general are both studied and treated. Cancers are very genetically diverse, and it's important to know what cancer subtype a patient has. Now you can think about collecting a patient's cells and studying how those cells respond to different therapies. The way a patient responds to treatment depends on the genetic makeup of the cancer.” The study was published on November 17, 2014, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
Northwestern University
BD Biosciences
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans